《大行报告》高盛升爱康医疗(01789.HK)及康基医疗(09997.HK)评级至「买入」 过度调整带来吸引切入点
高盛发表研究报告,指内地骨科手术/医疗消耗品企业自去年7月以来估值大幅收缩,忧虑国家带量采购带来的定价压力,爱康医疗(01789.HK)及康基医疗(09997.HK)股价自高位累跌分别60%及67%。投标规则细节有待公布,该行分析指潜在影响已大致反映,料带量采购後重新定价及销量反弹,将提振股价。
报告称,长期增长憧憬仍维持,受惠於手术程序渗透、进口替代品及新产品推出,认为股价过度调整带来吸引切入点,将爱康医疗及康基医疗评级各由「中性」升至「买入」,将爱康医疗今明两年盈测分别削26%及40%,以反映国家带量采购带来定价压力,目标价相应降22%,由19元下调至14.91元。
另高盛削康基医疗今明两年盈测26%及32%,以反映分销商审慎库存补货及国家带量采购带来的压力,目标价相应大削53%,目标价由30.9元降至14.4元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.